Microcoaxial phaco better than standard phaco

Article

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification.

Microcoaxial phacoemulsification induces significantly less keratometric changes and provides better visual acuity than standard phacoemulsification, according to Seyed Javad Hashemian and colleagues from the Fajr Hospital & Negah Eye Hospital, Tehran, Iran.

In a controlled prospective clinical trial, 69 eyes of subjects with senile cataract (grade 3 to 4 on the Lens opacities Classification System III) underwent phacoemulsification. The subjects were randomized to undergo either microcoaxial phaco (39 eyes; Sovereign WhiteStar; AMO) or conventional phaco (30 eyes; Legacy 20000, Everest; Alcon). In each case, the incision was made into a temporarily clear cornea and a hydrophobic acrylic flexible intraocular lens (Acrysof Natural, SN60AT; Alcon) was implanted.

The researchers found that the only statistically significant difference between the two groups was the surgically induced keratometric changes at five days postoperatively. (p=0.02).

At the study's conclusion, Dr Hashemian an colleagues concluded that, although both techniques were safe and effective for cataract surgery, microcoaxial phacoemulsification induced significantly less surgical keratometric changes and yielded better visual acuity in the early postoperative days.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.